Transcript Biotechnology - Dr. Sanjiv Kumar Maheshwari

BIOTECHNOLOGY
Unprecedented Growth
& Future Job Opportunity
Dr. Sanjiv Kumar Maheshwari
Professor and Dean,
IFTM University,
Moradabad
Biotechnology
Market and Growth Potential
Players
Opportunities
Why India
Courses offered by
School of Biotechnology, IFTM University
S
No
Course
1
B. Tech. (Biotechnology)
2
Duration
(Years)
Fee Per
semester
(RS.)
Eligibility
45000
Minimum 45% (40% for SC/ST) at
10+2 with Physics, Chemistry,
Mathematics / Biology
B. Sc.
3
(Biotechnology/Microbiology
/Food Technology)
20000
Minimum 45% (40% for SC/ST) at
10+2 with Physics, Chemistry,
Mathematics / Biology
3
M. Sc.
2
(Biotechnology/Microbiology
/Food Technology)
18000
Minimum 50% (45% for SC/ST) at
B.Sc. (Biotech.) / related Life
Sciences
4
M. Tech. (Biotechnology)
2
41000
Minimum 55% at B. Tech.
(Biotechnology)
5
Ph. D. (Biotechnology)
2
30000
As per latest UGC Norms
4
Biotech Market - Dynamic and growing
US$ 1 BN=
634 Crore
Size (2004-05)
US$ 1090.5 mn
Size (2010-11)
US$ 4 Bn
Largest segment
Biopharma
not to be confused with Pharma
Revenue from exports (2010-11)
56%
Growth of Sector (2011-12)
over 50%
Total investment (2003-04)
Rate of growth over 202-2003
US$ 137 million
26%
Biopharma leads the way
Composition of Indian Biotech Sector (2004-05)
Bio Agri
Bio-IT
6.95%
2.09 %
Bio Industrial
6.74%
Bio Services
8.95%
Bio Pharma
75.24 %
Source:Biospectrum-ABLE Survey
Biotechnology as a Sector
Third Largest Biotech Industry in Asia Pacific Region.
Second Highest number of USFDA approved plants.
US$ 3.7 BN to be spent on Biotechnology in India from 201217.
No. 1 producer of Hepatitis B Vaccine.
US$ 4.3 BN Bioeconomy (earning from Biotechnology) by the
end of 2015
US$ 200 BN Industry by 2025.
US$ 1 BN= 634 Crore
(Source: Make in India)
Market - A consistent uptrend
25% growth in investment
2002-03
70% growth in employment
74% growth in R&D
manpower
US$ 5 billion annual
revenues
2010
1 million skilled jobs
10% of global industry
Source: Confederation of Indian Industry (CII)
Indian Players
MNCs Scripting Success in India
Top MNCs World Wide
Market Cap in Q2 2015
Market Cap in 2014
(USD billion
(USD billions
USA
Switzerland
Switzerland
USA
USA
DEN
USA
FRA
USA
USA
GBR
USA
USA
USA
USA
GBR
USA
USA
276.9
272.6
240.4
211.7
162.3
147.0
145.1
136.0
117.7
116.7
114.1
105.0
97.0
91.7
90.4
87.7
79.2
69.9
277.8
229.8
258.5
205.4
166.9
125.4
109.0
138.1
93.1
38.2
128.9
97.6
79.7
104.1
89.5
88.9
76.6
67.9
Valeant Pharmaceuticals
CAN
67.7
47.9
Teva Pharmaceutical
ISR
54.5
49.0
Rank
Company
Country
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
Johnson & Johnson
Novartis
Roche
Pfizer
Merck
Novo Nordisk
Gilead Sciences
Sanofi
Amgen
Actavis
GlaxoSmithKline
Bristol-Myers Squibb
Biogen Idec
AbbVie
Celgene
AstraZeneca
Eli Lilly & Co
Abbott Laboratories
19
20
India: The Vaccine Hub
 Indian firms estimated to supply 90% of global
demand for the measles vaccine, in the near future.
 Serum Institute, Pune is believed to be the world`s
largest manufacturer of DPT vaccines.
 Indian Immunologicals operates the world`s second
largest plant for veterinary vaccines and is also the
world`s largest manufacturer of the vaccine against
Foot and Mouth Disease.
Invest in Agri Biotech
Ag.
Biotechnology
Biofertilisers
GM Crops and seeds
Biofuels
Biopesticides
The India Advantage
Excellent network
of research laboratories
Rich biodiversity
Well-developed
base industries
Extensive clinical trials
opportunities
Trained manpower
and knowledge base
The R & D Advantage
Genetic Engineering
Biotech
R&D
strengths
spread
across
range of
segments
DNA technologies
New Drug Delivery Systems
Rational drug design
Stem cell research
Bioinformatics